Ihosvany Fernndez Bello

List of Publications by Citations

32 papers	232 citations	11 h-index	15 g-index
32 ext. papers	287 ext. citations	3.4 avg, IF	2.72 L-index

#	Paper	IF	Citations
32	Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT in patients with severe haemophilia A without inhibitors. *Haemophilia*, **2017**, 23, e50-e54	3.3	28
31	Procoagulant profile in patients with immune thrombocytopenia. *British Journal of Haematology*, **2016**, 175, 925-934	4.5	25
30	Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. *Seminars in Hematology*, **2008**, 45, S64-7	4	22
29	Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. *Thrombosis and Haemostasis*, **2012**, 107, 88-98	7	21
28	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. *Thrombosis and Haemostasis*, **2019**, 119, 645-659	7	19
27	Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. *Thrombosis and Haemostasis*, **2014**, 112, 65-72	7	19
26	Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease. *Seminars in Thrombosis and Hemostasis*, **2015**, 41, 621-8	5.3	17
25	Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. *British Journal of Haematology*, **2020**, 189, 943-953	4.5	15
24	Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. *Orphanet Journal of Rare Diseases*, **2013**, 8, 81	4.2	12
23	Clinical and genetic findings in five female patients with haemophilia A: Identification of a novel missense mutation, p.Phe2127Ser. *Thrombosis and Haemostasis*, **2010**, 104, 718-23	7	12
22	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. *Thrombosis and Haemostasis*, **2013**, 109, 909-19	7	11
21	The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. *Haemophilia*, **2017**, 23, 868-876	3.3	7
20	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. *Aids*, **2016**, 30, 1141-2	3.5	7
19	Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. *Haemophilia*, **2020**, 26, e247-e249	3.3	5
18	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. *Archivos De Bronconeumologia*, **2020**, 58, 117-117	0.7	5
17	Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia. *British Journal of Clinical Pharmacology*, **2014**, 78, 674-6	3.8	2
16	Platelet Protein Glycosylation in Immune Thrombocytopenia. *Blood*, **2018**, 132, 2437-2437	2.2	2

List of Publications

15	Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein. *Blood*, **2019**, 134, 4929-4929	2.2	1
14	Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus. *Blood*, **2019**, 134, 1141-1141	2.2	1
13	Procoagulant Status In Patients With Immune Thrombocytopenia. *Blood*, **2013**, 122, 3528-3528	2.2	1
12	Immune thrombocytopenia - in defence of the platelet count. Response to Hill. *British Journal of Haematology*, **2018**, 182, 130-131	4.5	
11	Rotational thromboelastometry (ROTEM) in Behçet's disease. *Clinical Rheumatology*, **2013**, 32, 1691	3.9	
10	Thrombin Generation Related to Netosis in Patients with Systemic Lupus Erythematosus. *Blood*, **2020**, 136, 10-11	2.2	
9	Thein Vitroprocoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. *Blood*, **2020**, 136, 18-19	2.2	
8	Fibrin Polymerization Ability Influences Joint Condition in Patients with Severe Haemophilia. *Blood*, **2020**, 136, 17-18	2.2	
7	Monitoring of new therapies for hemophilia.. *Blood Coagulation and Fibrinolysis*, **2022**, 33, S3-S4	1	
6	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. *Blood*, **2018**, 132, 5048-5048	2.2	
5	Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments. *Blood*, **2019**, 134, 1089-1089	2.2	
4	Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab. *Blood*, **2019**, 134, 1118-1118	2.2	
3	Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. *Blood*, **2014**, 124, 1462-1462	2.2	
2	Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. *Blood*, **2012**, 120, 4658-4658	2.2	
1	Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. *Blood*, **2013**, 122, 1083-1083	2.2	